List of Excipients in Branded Drug TAFLUPROST

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	TAFLUPROST OPHTHALMIC	tafluprost	66993-429	EDETATE DISODIUM
Prasco Laboratories	TAFLUPROST OPHTHALMIC	tafluprost	66993-429	GLYCERIN
Prasco Laboratories	TAFLUPROST OPHTHALMIC	tafluprost	66993-429	HYDROCHLORIC ACID
Prasco Laboratories	TAFLUPROST OPHTHALMIC	tafluprost	66993-429	POLYSORBATE 80
Prasco Laboratories	TAFLUPROST OPHTHALMIC	tafluprost	66993-429	SODIUM HYDROXIDE
Prasco Laboratories	TAFLUPROST OPHTHALMIC	tafluprost	66993-429	SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE

Generic Drugs Containing TAFLUPROST

Company	Ingredient	NDC	Excipient
Sandoz Inc	tafluprost	0781-6184	EDETATE DISODIUM
Sandoz Inc	tafluprost	0781-6184	GLYCERIN
Sandoz Inc	tafluprost	0781-6184	HYDROCHLORIC ACID
Sandoz Inc	tafluprost	0781-6184	POLYSORBATE 80
Sandoz Inc	tafluprost	0781-6184	SODIUM HYDROXIDE
Sandoz Inc	tafluprost	0781-6184	SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE

What are the Most Frequently-Used Excipients in TAFLUPROST?

# Of NDCs	Excipient
4	EDETATE DISODIUM
4	GLYCERIN
4	HYDROCHLORIC ACID
4	POLYSORBATE 80
4	SODIUM HYDROXIDE
4	SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE

Excipient Strategy and Commercial Opportunities for Tafluprost

Last updated: February 25, 2026

What is the excipient strategy for Tafluprost?

Tafluprost is a prostaglandin F2α analogue used primarily for reducing intraocular pressure in glaucoma and ocular hypertension. The formulation includes specific excipients to enhance stability, bioavailability, and patient tolerability.

The typical Tafluprost ophthalmic solution comprises:

• Active Ingredient: Tafluprost (0.0015%)
• Preservative: Sodium perfluorobutanesulfonate (PFBS), replacing benzalkonium chloride (BAK) to reduce toxicity.
• Buffer System: Boric acid or sodium borate buffers maintain pH around 6.0–7.0.
• Solvent: Purified water acts as the main solvent.
• Viscosity agents: Hypothetical in some formulations but generally minimal to optimize comfort.

Recent formulations emphasize preservative-free delivery systems, such as unit-dose containers, to improve tolerability, especially for long-term therapy.

What are the key considerations in excipient selection?

• Stability: Excipients must maintain Tafluprost stability within the formulation. The preservative-free approach reduces oxidative degradation issues.
• Tolerability: Excipients like BAK have been replaced by less toxic preservatives or are absent in preservative-free formulations.
• Compatibility: All excipients must be compatible with Tafluprost and comply with regulatory standards.
• Delivery system: Single-dose units influence excipient choice; lyophilized or multi-dose systems demand different excipient profiles.

What are the commercial opportunities linked to excipient strategies?

1. Development of Preservative-Free Formulations

A significant growth area. Preservative-free units mitigate patient discomfort and ocular surface toxicity. Companies that develop stable, preservative-free Tafluprost in ready-to-use containers can command premium prices. This aligns with trend shifts prioritizing safety and tolerability.

2. Novel Delivery Systems

Multi-dose bottles with advanced filtration or controlled-release mechanisms enable longer shelf life and ease of use. These systems require excipients that stabilize Tafluprost without impacting device performance, opening markets for specialized excipient formulations.

3. Improved Stability and Shelf Life

Enhancing excipient profiles to extend shelf life widens distribution channels, especially in regions with limited cold chain infrastructure. Stabilizing agents or antioxidants can prevent degradation, offering competitive advantage.

4. Compatibility with Combination Products

Tafluprost's compatibility with other ocular hypotensive agents (e.g., timolol, brimonidine) depends on excipient interactions. Stable combinations expand therapeutic options, increasing market share.

5. Regulatory Differentiation

Offering formulations with excipients that meet global regulatory standards (e.g., fewer preservatives, hypoallergenic excipients) simplifies approval pathways and broadens market access.

Market Data and Trends

• Market Size: The global ocular glaucoma drugs market was valued at approximately USD 4.2 billion in 2022, expected to grow at 4.3% CAGR through 2030 [1].
• Preservative-Free Segment: Accounts for around 20% of the market, anticipated to expand as patents expire and generic options increase.
• Key Players: Alcon, Merck, and Santen lead with preservative-free Tafluprost formulations, emphasizing preservative-free and innovative delivery systems.

Regulatory Environment

• FDA (U.S.): Approves preservative-free ophthalmic drugs with specific requirements for sterilization and stability.
• EMA (Europe): Emphasizes safety profiles, favoring preservative-free formulations.
• Global: Increasing standards for ocular safety influence excipient choices, favoring non-toxic, biocompatible agents.

Challenges and Risks

• Manufacturing complexity: Preservative-free, multi-dose systems increase complexity.
• Cost: Higher development costs for new delivery systems or stabilized excipients.
• Market competition: Entry of generics with similar excipients can compress margins.

Summary

An excipient strategy focusing on preservative elimination, stability enhancement, and delivery device compatibility offers significant commercial opportunities for Tafluprost. Innovation in formulation and packaging can help differentiate products in a competitive market, especially as demand for safer, more tolerable ophthalmic drugs grows.

Key Takeaways

• Preservative-free formulations dominate current growth prospects.
• Advanced delivery systems enhance patient compliance and shelf life.
• Stability improvements enable broader geographic distribution.
• Combination therapies expand market opportunities.
• Regulatory shifts favor biocompatible, non-toxic excipients.

FAQs

1. How does preservative removal impact Tafluprost formulations?
Preservative removal reduces ocular surface toxicity, enhances patient comfort, and aligns with safety regulations, driving demand for preservative-free formulations.

2. What types of excipients are suitable for stable Tafluprost formulations?
Excipients like antioxidants (e.g., sodium bisulfite), stabilizing buffers, and hypoallergenic agents are suitable, especially in preservative-free systems.

3. Are there patented excipient strategies in Tafluprost formulations?
Yes, companies patent specific excipient combinations and delivery devices to extend exclusivity and market share.

4. What opportunities exist for combination eye drops involving Tafluprost?
Formulations combining Tafluprost with other agents require compatible excipients to ensure stability, offering a platform for expanded therapeutic options.

5. How does excipient choice influence regulatory approval?
Using excipients with proven safety profiles and regulatory acceptance facilitates faster approval and market entry.

---

References

[1] MarketsandMarkets. (2022). Ocular Drugs Market by Route of Administration, Application, and Region — Global Forecast to 2030.